977 / 1631
Palliative low dose RT
Number of patients
Number of sites
17
43
Histological subtype
DLBCL
MCL
14 (37 sites)
3 (6 sites)
Median time from diagnosis to
LDRT (months)
Median number of systemic
therapies
22 (0.23-195.1)
3 (0-7)
Treatment outcome
ORR
CR
LR
All
Site
-
Skin (23)
-
Nodal/EN (15)
-
Bone (5)
91% (39/43)
100% (23)
87% (13)
60% (3)
49% (21/43)
74%
27%
0
10%
4% (1/23)
8% (1/13)
77% (2/3)
Dose
-
4Gy (16)
-
6-8Gy (27)
88%
93%
63%
41%
14%
8%
Histology
-
DLBCL
-
MCL
92%
83%
51%
33%
12%
0
No of previous lines of treatment
-
≤2
-
>2
86%
96%
38%
59%
17%
5%
Brady ESTRO 2016
•
LC = 90%
•
Patients surviving > 6m: 7 sites
remaining controlled at 12 m
•
Max response duration was 127 months
(0.5-126.6)
•
median OS 2.4 m (0.03-126.7)
•
4-8 Gy